Actinium Pharmaceuticals highlights Iomab-ACT clinical results in CAR T-cell therapy at ASH 2026

Bitget2026/11/04 14:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Actinium Pharmaceuticals released three Iomab-ACT clinical abstracts for presentation at the 2026 American Society of Hematology meeting.
Memorial Sloan Kettering findings suggest potential for immune-cell depletion before investigational CAR T-cell therapy while preventing severe inflammatory and neurological toxicities.
A Phase 1b/2 trial evaluates Iomab-ACT conditioning before commercial CD19-directed CAR T-cell therapy, extending development beyond investigational treatments.
Preliminary severe sickle cell disease findings explore chemotherapy-free conditioning for donor engraftment; presentation is scheduled for December 13, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611040911PR_NEWS_USPR_____NY88516) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Actinium Pharmaceuticals highlights Iomab-ACT clinical results in CAR T-cell therapy at ASH 2026

You may also like

Crypto prices